Oral bisphosphonates and risk of ischemic stroke: a case–control study
- 13 October 2010
- journal article
- research article
- Published by Springer Nature in Osteoporosis International
- Vol. 22 (6) , 1773-1779
Abstract
Bisphosphonates have been associated with an increased risk of atrial fibrillation and may thus be associated with an increased risk of ischemic stroke. This would have substantial clinical and public health implications. We found no evidence of an association between bisphosphonate use and risk of ischemic stroke. Bisphosphonates have been associated with an increased risk of atrial fibrillation in some studies and may be associated with an increased risk of ischemic stroke. However, data regarding these possibilities are limited. We conducted a population-based case–control study of 6,257 female cases of ischemic stroke and 31,285 age- and gender-matched population controls. Data on bisphosphonate use, other medication use, comorbidity, and ischemic stroke were obtained from medical databases. Current bisphosphonate use was defined as at least one redeemed prescription within 90 days before diagnosis/index date. We estimated the odds ratio (OR) of ischemic stroke among users and nonusers of bisphosphonates using conditional logistic regression, controlling for potential confounding factors. One hundred eighty-two (2.9%) cases and 901 (2.9%) controls were current users of bisphosphonates. Etidronate and alendronate were prescribed with similar frequency among cases and controls. The adjusted OR of ischemic stroke for bisphosphonate users compared with nonusers was 0.97 (95% confidence interval [CI], 0.82–1.15). New and continuing bisphosphonate users had adjusted ORs for ischemic stroke of 1.16 (95% CI, 0.69–1.96) and 0.97 (95% CI, 0.81–1.16), respectively. Excluding patients with known atrial fibrillation/flutter yielded an OR of 1.00 (95% CI, 0.85–1.19). The OR for ischemic stroke was 0.59 (95% CI, 0.32–1.09) among patients with a history of previous hospitalization for cardiovascular disease and 1.07 (95% CI, 0.88–1.18) among those without (P < 0.001). The OR for former users was 1.23 (95% CI, 1.01–1.49). We found no evidence of an association of oral bisphosphonate use with the risk of ischemic stroke.Keywords
This publication has 32 references indexed in Scilit:
- Oral Bisphosphonates and Risk of Atrial Fibrillation and Flutter in Women: A Self-Controlled Case-Series Safety AnalysisPLOS ONE, 2009
- Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control studyBMJ, 2008
- Zoledronic Acid and Clinical Fractures and Mortality after Hip FractureNew England Journal of Medicine, 2007
- Alendronate and Atrial FibrillationNew England Journal of Medicine, 2007
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal OsteoporosisNew England Journal of Medicine, 2007
- A Single Infusion of Zoledronate Prevents Bone Loss After StrokeStroke, 2007
- Atrial Fibrillation and StrokeStroke, 1997
- Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long term prognosis (Oxfordshire community stroke project)BMJ, 1992
- Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.Stroke, 1991
- Meta-analysis of relation between cigarette smoking and stroke.BMJ, 1989